tiprankstipranks
Aurinia’s Lupus Drug LUPKYNIS Wins Approval in Japan
Company Announcements

Aurinia’s Lupus Drug LUPKYNIS Wins Approval in Japan

Story Highlights

Aurinia Pharmaceuticals (AUPH) has released an update.

Don't Miss our Black Friday Offers:

Aurinia Pharmaceuticals Inc. celebrates the Japanese approval of LUPKYNIS (voclosporin) to treat lupus nephritis, marking a significant milestone in collaboration with Otsuka Pharmaceutical. This approval, backed by the AURORA Clinical Program’s positive data, will address the high incidence of the disease in Japan. Additionally, Aurinia is set to receive a $10 million payment and royalties on net sales in Japan.

For further insights into AUPH stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskAurinia Pharmaceuticals Celebrates New Lupus Nephritis Guidelines
TipRanks Canadian Auto-Generated NewsdeskAurinia Highlights Lupus Nephritis Breakthroughs at ACR 2024
TipRanks Canadian Auto-Generated NewsdeskAurinia Pharmaceuticals Engages at London Conference
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App